---
document_datetime: 2025-12-02 06:16:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/giotrif.html
document_name: giotrif.html
version: success
processing_time: 0.1146795
conversion_datetime: 2025-12-28 08:56:57.640159
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Giotrif

[RSS](/en/individual-human-medicine.xml/66117)

##### Authorised

This medicine is authorised for use in the European Union

afatinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Giotrif](#news-on)
- [Related information](#related-information-618)
- [More information on Giotrif](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Giotrif. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Giotrif.

For practical information about using Giotrif, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Giotrif and what is it used for?

Giotrif is a medicine used to treat a type of lung cancer known as non-small cell lung cancer. It is used specifically in adults with advanced cancer in the following situations:

- when the cancer has a mutation in the gene for a protein called EGFR and has not been previously treated with tyrosine kinase inhibitor medicines.
- when the cancer is of a squamous cell type (from cells of the lining of the lungs) and has worsened despite treatment with platinum-based chemotherapy.

Giotrif contains the active substance afatinib.

## How is Giotrif used?

Treatment with Giotrif should be started and supervised by a doctor experienced in the use of cancer medicines.

Giotrif is available as tablets (20, 30, 40 and 50 mg) and is only available with a prescription. The recommended dose is 40 mg once daily but this may be increased to up to 50 mg per day in patients who tolerate the 40 mg dose, or interrupted and reduced in patients experiencing side effects. Treatment should continue for as long as possible, until the disease worsens or the side effects become too severe.

The tablets should be taken without food and no food should be eaten for at least 3 hours before and 1 hour after taking the tablets.

## How does Giotrif work?

The active substance in Giotrif, afatinib, is an ErbB family blocker. This means that it blocks the action of a group of proteins known as 'ErbB family' which are found on the surface of cancer cells and are involved in stimulating the cells to divide. By blocking these proteins, afatinib helps to control cell division and thereby slows down the growth and spread of the non-small cell lung cancer.

EGFR proteins are part of the ErbB family. Lung cancer cells with mutated EGFR proteins are particularly sensitive to afatinib.

## What benefits of Giotrif have been shown in studies?

Giotrif has been shown to significantly delay disease progression in patients with non-small cell lung cancer.

In a main study in 345 patients with tumours that have mutated EGFR genes, patients treated with Giotrif lived on average for 11 months without their disease getting worse compared with 7 months for patients who were treated with two other cancer medicines, pemetrexed and cisplatin.

In a second study in 795 patients with the squamous cell cancer type, patients treated with Giotrif lived on average for 2.6 months without their disease worsening compared with 1.9 months for patients treated with another cancer medicine, erlotinib.

## What are the risks associated with Giotrif?

The most common side effects with Giotrif (which may affect more than 1 in 10 people) are paronychia (nail bed infection), reduced appetite, epistaxis (nosebleeds), diarrhoea, nausea (feeling sick), vomiting, stomatitis (inflammation of the lining of the mouth), rash, acneiform dermatitis (acne-like skin conditions), pruritus (itching), and dry skin. For the full list of all side effects and restrictions with Giotrif, see the package leaflet.

## Why is Giotrif approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Giotrif outweigh its risks and recommended that it be granted marketing authorisation in the EU. The CHMP considered that in patients treated with Giotrif the improvement in progression-free survival (how long they lived without the disease getting worse) was a meaningful benefit for patients. In addition, the side effects of the medicine were considered to be manageable and similar to those seen with medicines of the same class.

## What measures are being taken to ensure the safe and effective use of Giotrif?

A risk management plan has been developed to ensure that Giotrif is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Giotrif, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Giotrif

The European Commission granted a marketing authorisation valid throughout the European Union for Giotrif on 25 September 2013.

For more information about treatment with Giotrif, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Giotrif : EPAR - Summary for the public

Reference Number: EMA/473990/2013

English (EN) (80.92 KB - PDF)

**First published:** 16/10/2013

**Last updated:** 24/05/2016

[View](/en/documents/overview/giotrif-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-495)

български (BG) (107.16 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/bg/documents/overview/giotrif-epar-summary-public_bg.pdf)

español (ES) (75.42 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/es/documents/overview/giotrif-epar-summary-public_es.pdf)

čeština (CS) (104.45 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/cs/documents/overview/giotrif-epar-summary-public_cs.pdf)

dansk (DA) (79.34 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/da/documents/overview/giotrif-epar-summary-public_da.pdf)

Deutsch (DE) (81.46 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/de/documents/overview/giotrif-epar-summary-public_de.pdf)

eesti keel (ET) (78.04 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/et/documents/overview/giotrif-epar-summary-public_et.pdf)

ελληνικά (EL) (107.62 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/el/documents/overview/giotrif-epar-summary-public_el.pdf)

français (FR) (100.33 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/fr/documents/overview/giotrif-epar-summary-public_fr.pdf)

hrvatski (HR) (100.33 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/hr/documents/overview/giotrif-epar-summary-public_hr.pdf)

italiano (IT) (79.5 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/it/documents/overview/giotrif-epar-summary-public_it.pdf)

latviešu valoda (LV) (100.81 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/lv/documents/overview/giotrif-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (102.89 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/lt/documents/overview/giotrif-epar-summary-public_lt.pdf)

magyar (HU) (99.19 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/hu/documents/overview/giotrif-epar-summary-public_hu.pdf)

Malti (MT) (105.29 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/mt/documents/overview/giotrif-epar-summary-public_mt.pdf)

Nederlands (NL) (79.62 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/nl/documents/overview/giotrif-epar-summary-public_nl.pdf)

polski (PL) (105.03 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/pl/documents/overview/giotrif-epar-summary-public_pl.pdf)

português (PT) (80.22 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/pt/documents/overview/giotrif-epar-summary-public_pt.pdf)

română (RO) (101.41 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/ro/documents/overview/giotrif-epar-summary-public_ro.pdf)

slovenčina (SK) (103.96 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/sk/documents/overview/giotrif-epar-summary-public_sk.pdf)

slovenščina (SL) (97.93 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/sl/documents/overview/giotrif-epar-summary-public_sl.pdf)

Suomi (FI) (79.07 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/fi/documents/overview/giotrif-epar-summary-public_fi.pdf)

svenska (SV) (79.69 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

24/05/2016

[View](/sv/documents/overview/giotrif-epar-summary-public_sv.pdf)

## Product information

Giotrif : EPAR - Product information

English (EN) (1.07 MB - PDF)

**First published:** 16/10/2013

**Last updated:** 31/03/2025

[View](/en/documents/product-information/giotrif-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-57)

български (BG) (1.16 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/bg/documents/product-information/giotrif-epar-product-information_bg.pdf)

español (ES) (1.08 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/es/documents/product-information/giotrif-epar-product-information_es.pdf)

čeština (CS) (1.21 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/cs/documents/product-information/giotrif-epar-product-information_cs.pdf)

dansk (DA) (1.06 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/da/documents/product-information/giotrif-epar-product-information_da.pdf)

Deutsch (DE) (1.09 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/de/documents/product-information/giotrif-epar-product-information_de.pdf)

eesti keel (ET) (1.1 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/et/documents/product-information/giotrif-epar-product-information_et.pdf)

ελληνικά (EL) (1.22 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/el/documents/product-information/giotrif-epar-product-information_el.pdf)

français (FR) (1.23 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/fr/documents/product-information/giotrif-epar-product-information_fr.pdf)

hrvatski (HR) (1.16 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/hr/documents/product-information/giotrif-epar-product-information_hr.pdf)

íslenska (IS) (1.05 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/is/documents/product-information/giotrif-epar-product-information_is.pdf)

italiano (IT) (1.14 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/it/documents/product-information/giotrif-epar-product-information_it.pdf)

latviešu valoda (LV) (1.17 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/lv/documents/product-information/giotrif-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.17 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/lt/documents/product-information/giotrif-epar-product-information_lt.pdf)

magyar (HU) (1.14 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/hu/documents/product-information/giotrif-epar-product-information_hu.pdf)

Malti (MT) (1.19 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/mt/documents/product-information/giotrif-epar-product-information_mt.pdf)

Nederlands (NL) (1.11 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/nl/documents/product-information/giotrif-epar-product-information_nl.pdf)

norsk (NO) (1.04 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/no/documents/product-information/giotrif-epar-product-information_no.pdf)

polski (PL) (1.21 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/pl/documents/product-information/giotrif-epar-product-information_pl.pdf)

português (PT) (1.04 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/pt/documents/product-information/giotrif-epar-product-information_pt.pdf)

română (RO) (1.12 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/ro/documents/product-information/giotrif-epar-product-information_ro.pdf)

slovenčina (SK) (1.17 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/sk/documents/product-information/giotrif-epar-product-information_sk.pdf)

slovenščina (SL) (1.16 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/sl/documents/product-information/giotrif-epar-product-information_sl.pdf)

Suomi (FI) (1.07 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/fi/documents/product-information/giotrif-epar-product-information_fi.pdf)

svenska (SV) (1.05 MB - PDF)

**First published:**

16/10/2013

**Last updated:**

31/03/2025

[View](/sv/documents/product-information/giotrif-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000261894 31/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Giotrif : EPAR - All Authorised presentations

English (EN) (18.02 KB - PDF)

**First published:** 16/10/2013

**Last updated:** 27/03/2014

[View](/en/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-145)

български (BG) (48.66 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/bg/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_bg.pdf)

español (ES) (18.75 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/es/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_es.pdf)

čeština (CS) (52.79 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/cs/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.66 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/da/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (16.81 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/de/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (19.38 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/et/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.08 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/el/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_el.pdf)

français (FR) (18.44 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/fr/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (54.4 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/hr/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (49.52 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/is/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.44 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/it/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (35.87 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/lv/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (38.73 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/lt/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.76 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/hu/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (45.17 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/mt/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.01 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/nl/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (18.68 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/no/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_no.pdf)

polski (PL) (27.63 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/pl/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_pl.pdf)

português (PT) (18.68 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/pt/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.56 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/ro/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (27.39 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/sk/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (26.76 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/sl/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (19.61 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/fi/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.89 KB - PDF)

**First published:**

16/10/2013

**Last updated:**

27/03/2014

[View](/sv/documents/all-authorised-presentations/giotrif-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Giotrif Active substance afatinib International non-proprietary name (INN) or common name afatinib Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01XE13

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Giotrif as monotherapy is indicated for the treatment of

- Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s);
- locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.

## Authorisation details

EMA product number EMEA/H/C/002280 Marketing authorisation holder

Boehringer Ingelheim International GmbH

Binger Strasse 173

Opinion adopted 25/07/2013 Marketing authorisation issued 25/09/2013 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Giotrif : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.73 KB - PDF)

**First published:** 31/03/2025

[View](/en/documents/procedural-steps-after/giotrif-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Giotrif : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (175.85 KB - PDF)

**First published:** 06/11/2014

**Last updated:** 31/03/2025

[View](/en/documents/procedural-steps-after/giotrif-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Giotrif-H-C-2280-II-0012 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/CHMP/206630/2016

English (EN) (2.45 MB - PDF)

**First published:** 24/05/2016

**Last updated:** 24/05/2016

[View](/en/documents/variation-report/giotrif-h-c-2280-ii-0012-epar-assessment-report-extension_en.pdf)

CHMP post-authorisation summary of positive opinion for Giotrif

Adopted

Reference Number: EMA/CHMP/100611/2016

English (EN) (71.91 KB - PDF)

**First published:** 26/02/2016

**Last updated:** 26/02/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-giotrif_en.pdf)

## Initial marketing authorisation documents

Giotrif : EPAR - Public assessment report

Adopted

Reference Number: EMA/491185/2013

English (EN) (4.95 MB - PDF)

**First published:** 16/10/2013

**Last updated:** 16/10/2013

[View](/en/documents/assessment-report/giotrif-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Giotrif

Adopted

Reference Number: EMA/CHMP/447957/2013

English (EN) (63.61 KB - PDF)

**First published:** 26/07/2013

**Last updated:** 26/07/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-giotrif_en.pdf)

#### News on Giotrif

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2016) 26/02/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC002280II0012) (variation II/0012)

#### More information on Giotrif

- [EMEA-001596-PIP02-17-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001596-pip02-17-m02)
- [Japanese REal-world data for treatment of afatinib (GIotrif®) in first-line setting and Subsequent Therapies for patients with advanced EGFR mutation-positive lung adenocarcinoma (J-REGISTER) - post-authorisation study](https://catalogues.ema.europa.eu/study/40323)
- [A Multicentre, Cohort Study to Assess the Impact on SYMptom Burden and Patient Health-related Quality of Life of Afatinib Treatment in Advanced Non-small Cell Lung Cancer in a Real World Setting in Greece (SYM-Less) - post-authorisation study](https://catalogues.ema.europa.eu/study/46770)
- [START: Real-world study on sequential therapy with afatinib as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC) - post-authorisation study](https://catalogues.ema.europa.eu/study/44236)
- [A regulatory requirement post-marketing surveillance study to monitor the safety and efficacy of GIOTRIF®(afatinib dimaleate, 20mg, 30mg, 40mg, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutation(s) (GIOTRIF rPMS in Korean patients with NSCLC) - post-authorisation study](https://catalogues.ema.europa.eu/study/20368)
- [Evaluation of the impact of a nurse-led telephone follow-up on treatment compliance of patients treated from a locally advanced or metastatic non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation(s).The PARTAGE study. - post-authorisation study](https://catalogues.ema.europa.eu/study/12955)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 31/03/2025

## Share this page

[Back to top](#main-content)